TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Medicure ( (TSE:MPH) ) has provided an announcement.
Medicure Inc. has announced the acquisition of Gateway Medical Pharmacy through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., as part of its strategy to expand its direct-to-consumer pharmacy business. This acquisition is expected to enhance Medicure’s service offerings, support the growth of its products like ZYPITAMAG, and improve access and adherence for patients without incurring new debt or financing costs.
More about Medicure
Medicure Inc. is a pharmaceutical company focused on developing and commercializing healthcare products for patients and prescribers in the United States. The company primarily markets AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets through its U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, a pharmacy subsidiary that provides medication access across all 50 states, Washington D.C., and Puerto Rico with exceptional customer service and free home delivery.
YTD Price Performance: -13.37%
Average Trading Volume: 2,844
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$8.45M
For a thorough assessment of MPH stock, go to TipRanks’ Stock Analysis page.